← Patent-cliff monitor Loss of exclusivity December 2034 latest FDA-listed patent expiry
Drug detail Brand name SYNJARDY XR Active ingredient EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE Strength 25MG;1GM Dosage form TABLET, EXTENDED RELEASE Route ORAL Modality Small molecule FDA approval December 2016 Marketing status RX
Listed patents Patent Expires Type 9949998*PED December 2034 — 9949997*PED November 2034 — 10258637*PED October 2034 — 12433906*PED October 2034 — 11090323*PED October 2034 — 11833166*PED October 2034 — 9949998 June 2034 use U-2290 9949997 May 2034 use U-3533 10258637 April 2034 use U-2290 12433906 April 2034 use U-4296 11666590 April 2034 use U-4154 12263153 April 2034 use U-4154 12427162 April 2034 use U-4287 11833166 April 2034 use U-3776 11090323 April 2034 use U-3193 10596120*PED September 2032 — 10596120 March 2032 product 12115179*PED August 2030 — 12115179 February 2030 use U-4023 7579449*PED February 2029 — 7579449 August 2028 substance 7713938*PED October 2027 — 7713938 April 2027 substance, product
Regulatory exclusivity Code Expires PED December 2026 M-296 June 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.